{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:17:36Z","timestamp":1787048256754,"version":"build-2736575974"},"reference-count":25,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:p>Opsoclonus-myoclonus syndrome (OMS) is an autoimmune disorder with serious neurodevelopmental morbidity and limited treatment options. We treated a toddler with moderately severe OMS with rituximab, a monoclonal anti-B cell antibody. The patient's clinical response was documented on videotape and scored with the OMS Evaluation Scale. Cerebrospinal fluid lymphocyte subsets were evaluated by flow-cytometric immunophenotyping, with a comprehensive panel of monoclonal antibodies. Eradication of cerebrospinal fluid B cells, which previously were expanded, was associated with dramatic clinical improvement. There also were secondary changes in other lymphocyte subsets that might be relevant to the clinical response and lack of serious infections. In addition to clarifying the immune response to B-cell depletion, these data reveal a promising new therapy for OMS that warrants a phase I clinical trial.<\/jats:p>","DOI":"10.1542\/peds.2004-0845","type":"journal-article","created":{"date-parts":[[2004,12,16]],"date-time":"2004-12-16T01:33:22Z","timestamp":1103160802000},"page":"e115-e119","source":"Crossref","is-referenced-by-count":59,"title":["Immunologic and Clinical Responses to Rituximab in a Child With Opsoclonus-Myoclonus Syndrome"],"prefix":"10.1542","volume":"115","author":[{"given":"Michael R.","family":"Pranzatelli","sequence":"first","affiliation":[{"name":"Departments of Neurology"},{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Tate","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Travelstead","sequence":"additional","affiliation":[{"name":"Medical Microbiology and Immunology, Southern Illinois University School of Medicine, Springfield, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Longee","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Carilion Roanoke Community Hospital, Roanoke, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2005,1,1]]},"reference":[{"key":"2021121011062393300_R1","doi-asserted-by":"crossref","unstructured":"Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs.\u20082002;13(suppl 2):S3\u2013S10","DOI":"10.1097\/00001813-200211002-00002"},{"key":"2021121011062393300_R2","unstructured":"Grillo-Lo\u0301pez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol.\u20081999;26(suppl 14):66\u201373"},{"key":"2021121011062393300_R3","doi-asserted-by":"crossref","unstructured":"Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune hemolytic anemia with rituximab. Lancet.\u20082001;358:1511\u20131513","DOI":"10.1016\/S0140-6736(01)06573-4"},{"key":"2021121011062393300_R4","doi-asserted-by":"crossref","unstructured":"Faurschou M, Hasselbalch HC, Nielsen OJ. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia. Eur J Haematol.\u20082001;66:408\u2013411","DOI":"10.1034\/j.1600-0609.2001.066006408.x"},{"key":"2021121011062393300_R5","doi-asserted-by":"crossref","unstructured":"Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis.\u20082002;61:883\u2013888","DOI":"10.1136\/ard.61.10.883"},{"key":"2021121011062393300_R6","doi-asserted-by":"crossref","unstructured":"Anolik J, Campbell D, Felgar R, et al. The relationship of Fc\u03b3RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum.\u20082003;48:455\u2013459","DOI":"10.1002\/art.10764"},{"key":"2021121011062393300_R7","doi-asserted-by":"crossref","unstructured":"Pestronk J, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. Neurol Neurosurg Psychiatry.\u20082003;74:485\u2013489","DOI":"10.1136\/jnnp.74.4.485"},{"key":"2021121011062393300_R8","doi-asserted-by":"crossref","unstructured":"Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum.\u20082001;44:2836\u20132840","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W"},{"key":"2021121011062393300_R9","doi-asserted-by":"crossref","unstructured":"Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry.\u20081962;25:221\u2013276","DOI":"10.1136\/jnnp.25.3.271"},{"key":"2021121011062393300_R10","doi-asserted-by":"crossref","unstructured":"Antunes NL, KhakooY, Mattay KK, et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol.\u20082000;22:315\u2013320","DOI":"10.1097\/00043426-200007000-00007"},{"key":"2021121011062393300_R11","doi-asserted-by":"crossref","unstructured":"Bataller L, Rosenfeld MR, Graus F, et al. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol.\u20082003;53:347\u2013353","DOI":"10.1002\/ana.10462"},{"key":"2021121011062393300_R12","doi-asserted-by":"crossref","unstructured":"Chung JB, Wells AD, Adler S, et al. Incomplete activation of CD4 T cells by antigen-presenting transitional immature B cells: implications for peripheral B and T cell responsiveness. J Immunol.\u20082003;171:1758\u20131767","DOI":"10.4049\/jimmunol.171.4.1758"},{"key":"2021121011062393300_R13","doi-asserted-by":"crossref","unstructured":"Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Disord.\u20082004;19:770\u2013777","DOI":"10.1002\/mds.20125"},{"key":"2021121011062393300_R14","unstructured":"Pranzatelli MR, Tate ED, Travelstead AL, Verhulst SJ. CSF B-cell expansion in opsoclonus-myoclonus: effect of rituximab, an anti-B-cell monoclonal antibody. Neurology.\u20082003;60(suppl 1):A395"},{"key":"2021121011062393300_R15","doi-asserted-by":"crossref","unstructured":"Pranzatelli MR, Tate ED, Galvan I, Wheeler A. A controlled pilot study of piracetam for pediatric opsoclonus-myoclonus. Clin Neuropharmacol.\u20082001;24:352\u2013357","DOI":"10.1097\/00002826-200111000-00007"},{"key":"2021121011062393300_R16","doi-asserted-by":"crossref","unstructured":"Pranzatelli MR, Travelstead AL, Tate ED, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology.\u20082004;62:1526\u20131532","DOI":"10.1212\/WNL.62.9.1526"},{"key":"2021121011062393300_R17","doi-asserted-by":"crossref","unstructured":"Svenningsson A, Anderson O, Edsbagge M, et al. Lymphocyte phenotype and subset distribution in normal cerebrospinal fluid. J Neuroimmunol.\u20081995;63:39\u201346","DOI":"10.1016\/0165-5728(95)00126-3"},{"key":"2021121011062393300_R18","doi-asserted-by":"crossref","unstructured":"Comans-Bitter WM, De Groot R, Van den Beemd R, et al. Immunophenotyping of blood lymphocytes in childhood: reference values for lymphocyte subpopulations. J Pediatr.\u20081997;130:388\u2013393","DOI":"10.1016\/S0022-3476(97)70200-2"},{"key":"2021121011062393300_R19","doi-asserted-by":"crossref","unstructured":"Hammer MS, Larsen MB, Stack CV. Outcome of children with opsoclonus-myoclonus regardless of etiology. Pediatr Neurol.\u20081995;13:21\u201324","DOI":"10.1016\/0887-8994(95)00083-R"},{"key":"2021121011062393300_R20","doi-asserted-by":"crossref","unstructured":"Pranzatelli MR, Tate ED, Wheeler A. Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatr Neurol.\u20082002;27:384\u2013387","DOI":"10.1016\/S0887-8994(02)00457-5"},{"key":"2021121011062393300_R21","doi-asserted-by":"crossref","unstructured":"Papero PH, Pranzatelli MR, Margolis JL, et al. Neurobehavioral and psychosocial functioning of children with opsoclonus-myoclonus syndrome. Dev Med Child Neurol.\u20081995;37:915\u2013932","DOI":"10.1111\/j.1469-8749.1995.tb11944.x"},{"key":"2021121011062393300_R22","doi-asserted-by":"crossref","unstructured":"Pohl KRE, Pritchard J, Wilson J. Neurological sequelae of the dancing eye syndrome. Eur J Pediatr.\u20081996;155:237\u2013244","DOI":"10.1007\/BF01953945"},{"key":"2021121011062393300_R23","doi-asserted-by":"crossref","unstructured":"Pranzatelli MR. The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol.\u20081996;19:1\u201347","DOI":"10.1097\/00002826-199619010-00001"},{"key":"2021121011062393300_R24","doi-asserted-by":"crossref","unstructured":"Hickey WF. Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol.\u20081999;11:125\u2013137","DOI":"10.1006\/smim.1999.0168"},{"key":"2021121011062393300_R25","doi-asserted-by":"crossref","unstructured":"Connolly AM, Pestronk A, Shobhna M, et al. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr.\u20081997;130:878\u2013884","DOI":"10.1016\/S0022-3476(97)70272-5"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/1\/e115\/1003714\/zpe0010500e115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/1\/e115\/1003714\/zpe0010500e115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:09:18Z","timestamp":1639181358000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/115\/1\/e115\/66982\/Immunologic-and-Clinical-Responses-to-Rituximab-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,1,1]]},"published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-0845","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}